BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

317 related articles for article (PubMed ID: 30667073)

  • 21. Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells.
    Le Flahec G; Badic B; Guibourg B; Doucet L; Bail JP; Marcorelles P; Schick U; Uguen A
    Hum Pathol; 2018 Feb; 72():135-143. PubMed ID: 29208565
    [TBL] [Abstract][Full Text] [Related]  

  • 22. PD-L1 expression in HNPCC-associated colorectal cancer.
    Shiraliyeva N; Friedrichs J; Buettner R; Friedrichs N
    Pathol Res Pract; 2017 Dec; 213(12):1552-1555. PubMed ID: 29033182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Immunohistochemistry for PMS2 and MSH6 alone can replace a four antibody panel for mismatch repair deficiency screening in colorectal adenocarcinoma.
    Hall G; Clarkson A; Shi A; Langford E; Leung H; Eckstein RP; Gill AJ
    Pathology; 2010; 42(5):409-13. PubMed ID: 20632815
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Correlation of mismatch repair deficiency with clinicopathological features and programmed death-ligand 1 expression in thyroid carcinoma.
    Qiao PP; Tian KS; Han LT; Ma B; Shen CK; Zhao RY; Zhang Y; Wei WJ; Chen XP
    Endocrine; 2022 Jun; 76(3):660-670. PubMed ID: 35366156
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clear cell carcinoma of the uterine cervix; an unusual HPV-independent tumor: Clinicopathological features, PD-L1 expression, and mismatch repair protein deficiency status of 16 cases.
    Bulutay P; Eren ÖC; Özen Ö; Haberal AN; Kapucuoğlu N
    Turk J Obstet Gynecol; 2023 Sep; 20(3):164-173. PubMed ID: 37667475
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Peritumoral granulomatous reaction in endometrial carcinoma: association with DNA mismatch repair protein deficiency, particularly loss of PMS2 expression.
    Stewart CJR; Pearn A; Pachter N; Tan A
    Histopathology; 2018 Sep; 73(3):428-437. PubMed ID: 29710374
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Programmed death-ligand 1 expression in gastric cancer: correlation with mismatch repair deficiency and HER2-negative status.
    Wang L; Zhang Q; Ni S; Tan C; Cai X; Huang D; Sheng W
    Cancer Med; 2018 Jun; 7(6):2612-2620. PubMed ID: 29673110
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Lymphoepithelioma-Like Carcinoma of the Uterine Cervix: A Pathologic Study of Eight Cases With Emphasis on the Association With Human Papillomavirus.
    Pinto A; Huang M; Nadji M
    Am J Clin Pathol; 2019 Jan; 151(2):231-239. PubMed ID: 30321260
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor-infiltrating lymphocytes, PD-L1, and MMR-deficiency combined characterization may identify subgroups of rectal cancer patients who would benefit from immunotherapy.
    Giatromanolaki A; Kavazis C; Gkegka AG; Kouroupi M; Tsaroucha A; Pitiakoudis M; Koukourakis MI
    Immunobiology; 2023 Nov; 228(6):152756. PubMed ID: 38860277
    [TBL] [Abstract][Full Text] [Related]  

  • 30. PD-L1/PD-1 Expression in Endometrial Clear Cell Carcinoma: A Potential Surrogate Marker for Clinical Trials.
    Jin C; Hacking S; Liang S; Nasim M
    Int J Surg Pathol; 2020 Feb; 28(1):31-37. PubMed ID: 31311367
    [No Abstract]   [Full Text] [Related]  

  • 31. Association of Merkel Cell Polyomavirus Status With p53, RB1, and PD-L1 Expression and Patient Prognosis in Merkel Cell Carcinomas: Clinical, Morphologic, and Immunohistochemical Evaluation of 17 Cases.
    Öğüt B; Bayram EK; İnan MA; Kestel S; Erdem Ö
    Appl Immunohistochem Mol Morphol; 2023 Jul; 31(6):371-378. PubMed ID: 37126387
    [TBL] [Abstract][Full Text] [Related]  

  • 32. PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells: Differences Across Histologic and TCGA-based Molecular Subgroups.
    Pasanen A; Ahvenainen T; Pellinen T; Vahteristo P; Loukovaara M; Bützow R
    Am J Surg Pathol; 2020 Feb; 44(2):174-181. PubMed ID: 31651527
    [TBL] [Abstract][Full Text] [Related]  

  • 33. PD-L1 Expression in Small Cell and Large Cell Neuroendocrine Carcinomas of Lung: an Immunohistochemical Study with Review of Literature.
    Guleria P; Kumar S; Malik PS; Jain D
    Pathol Oncol Res; 2020 Oct; 26(4):2363-2370. PubMed ID: 32506394
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinicopathological features of programmed death ligand 1 expression with tumor-infiltrating lymphocyte, mismatch repair, and Epstein-Barr virus status in a large cohort of gastric cancer patients.
    Kawazoe A; Kuwata T; Kuboki Y; Shitara K; Nagatsuma AK; Aizawa M; Yoshino T; Doi T; Ohtsu A; Ochiai A
    Gastric Cancer; 2017 May; 20(3):407-415. PubMed ID: 27629881
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Investigation of the relationship between immune checkpoints and mismatch repair deficiency in recurrent and nonrecurrent glioblastoma.
    Çakır E; Saygın İ; Ercin ME
    Turk J Med Sci; 2021 Aug; 51(4):1800-1808. PubMed ID: 33600097
    [TBL] [Abstract][Full Text] [Related]  

  • 36. PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas.
    Jenkins TM; Cantrell LA; Stoler MH; Mills AM
    Int J Gynecol Pathol; 2021 Nov; 40(6):563-574. PubMed ID: 33323859
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Characterization of immune regulatory molecules B7-H4 and PD-L1 in low and high grade endometrial tumors.
    Bregar A; Deshpande A; Grange C; Zi T; Stall J; Hirsch H; Reeves J; Sathyanarayanan S; Growdon WB; Rueda BR
    Gynecol Oncol; 2017 Jun; 145(3):446-452. PubMed ID: 28347512
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High-Grade Neuroendocrine Carcinoma of the Head and Neck: Human Papillomavirus Status and PD-L1 Expression.
    Bahr K; Zimmer S; Springer E; Fottner C; Becker S; Ernst BP; Matthias C; Künzel J
    ORL J Otorhinolaryngol Relat Spec; 2019; 81(5-6):309-316. PubMed ID: 31550725
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Programmed Death-Ligand 1 Expression, Microsatellite Instability, Epstein-Barr Virus, and Human Papillomavirus in Nasopharyngeal Carcinomas of Patients from the Philippines.
    Chang AMV; Chiosea SI; Altman A; Pagdanganan HA; Ma C
    Head Neck Pathol; 2017 Jun; 11(2):203-211. PubMed ID: 27807760
    [TBL] [Abstract][Full Text] [Related]  

  • 40. PD-L1 and HLA-class I expression status and their therapeutic implication in oesophageal small-cell carcinoma.
    Yamashita S; Abe H; Yamashita H; Yagi K; Seto Y; Ushiku T
    Histopathology; 2023 Aug; 83(2):264-275. PubMed ID: 37071391
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.